Valeritas (OTCMKTS:VLRXQ) and Bio-Rad Laboratories (NYSE:BIO) Financial Review

Valeritas (OTCMKTS:VLRXQ) and Bio-Rad Laboratories (NYSE:BIO) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, analyst recommendations, dividends, risk, earnings, valuation and institutional ownership.

Earnings & Valuation

This table compares Valeritas and Bio-Rad Laboratories”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Valeritas	N/A	N/A	N/A	N/A	N/A
Bio-Rad Laboratories	$2.58 billion	3.01	$759.90 million	$27.91	10.33

Bio-Rad Laboratories has higher revenue and earnings than Valeritas.

Insider & Institutional Ownership

65.2% of Bio-Rad Laboratories shares are held by institutional investors. 1.0% of Valeritas shares are held by company insiders. Comparatively, 30.3% of Bio-Rad Laboratories shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Profitability

This table compares Valeritas and Bio-Rad Laboratories’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Valeritas	N/A	N/A	N/A
Bio-Rad Laboratories	29.42%	3.86%	2.70%

Analyst Ratings

This is a breakdown of recent ratings and target prices for Valeritas and Bio-Rad Laboratories, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Valeritas	0	0	0	0	0.00
Bio-Rad Laboratories	1	3	2	0	2.17

Bio-Rad Laboratories has a consensus target price of $339.75, suggesting a potential upside of 17.86%. Given Bio-Rad Laboratories’ stronger consensus rating and higher probable upside, analysts clearly believe Bio-Rad Laboratories is more favorable than Valeritas.

Summary

Bio-Rad Laboratories beats Valeritas on 9 of the 9 factors compared between the two stocks.

About Valeritas

Valeritas Holdings, Inc., a commercial-stage medical technology company, focuses on the development and commercialization of technologies to treat patients with Type 2 diabetes in the United States. The company offers V-Go, a wearable insulin delivery device for basal-bolus therapy. It also develops V-Go Prefill that is in the design-development stage for eliminating the device-filling process and the need for EZ fill refrigeration for patients with Type 2 diabetes; and V-Go SIM for real-time tracking information of basal and bolus dosing utilization. The company sells V-Go to third-party wholesalers and medical supply distributors. Valeritas Holdings, Inc. was founded in 2006 and is headquartered in Bridgewater, New Jersey.

About Bio-Rad Laboratories

Bio-Rad Laboratories, Inc. manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets. It also designs, manufactures, markets, and supports test systems, informatics systems, test kits, and specialized quality controls for hospitals, diagnostic reference, transfusion, and physician office laboratories. The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.